🇺🇸 FDA

Drug profile · INN

docetaxel

DOCETAXEL MYLAN

approved L01CD02
US status
approved
Patents linked
3
News articles
0

Quick answer

docetaxel (DOCETAXEL MYLAN) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN docetaxel
Brand DOCETAXEL MYLAN
Route INJECTION
Formulation INJECTABLE
ATC code L01CD02
Originator Teva Pharma GmbH

Related patents

Search patents →

  1. US 10080720

    Pharmaceutical composition containing docetaxel

    Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8481511

    Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process

    Expires Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8044093

    Pharmaceutical compositions comprising docetaxel and methods for preparation thereof

    Expires Mon Oct 20 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is docetaxel?

docetaxel (DOCETAXEL MYLAN) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for docetaxel?

DOCETAXEL MYLAN is a marketed brand name for docetaxel. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of docetaxel?

docetaxel has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.